Kaiser Permanente Health Plan of Mid-Atlantic States, Inc.
Adrenergics, Aromatic, Non-Catecholamine Agents
Prior Authorization (PA)
Pharmacy Benefits Prior Authorization Help Desk
Length of Authorizations: Initial- 12 months; Continuation- 12 months

Instructions:

This form is used by Kaiser Permanente and/or participating providers for coverage of **Adrenergics, Aromatic, Non-Catecholamine Agents.** Please complete all sections, incomplete forms will delay processing. Fax this form back to Kaiser Permanente within 24 hours fax: 1-866-331-2104. If you have any questions or concerns, please call 1-866-331-2103.

Requests will not be considered unless all sections are complete.

KP-MAS Formulary can be found at: Pharmacy | Community Provider Portal | Kaiser Permanente

Medications:

• ADZENYS XR-ODT (therapy for ≥ 6 years of age) • DYANAVEL XR SUER (therapy for ≥ 6 years of age) • EVEKEO ODT (therapy for ≥ 6 years of age)	• MYDAYIS CP24 (therapy for ≥ 13 years of age) • VYVANSE CAPS, VYVANSE CHEW (therapy for ≥ 6 years of age)

1 – Patient Information

Patient Name: _____ Kaiser Medical ID#: _____ Date of Birth: _____

2 – Prescriber Information

Prescriber Name: _____ Specialty: _____ NPI: _____

Prescriber Address: _____

Prescriber Phone #: _____Prescriber Fax #: _____

3 – Pharmacy Information

Pharmacy Name: _____ Pharmacy NPI: _____

Pharmacy Phone #_____ Pharmacy Fax #: _____

4 – Drug Therapy Requested

Drug 1: Name/Strength/Formulation: _____
Sig: _____

Drug 2: Name/Strength/Formulation: _____
Sig: _____

5– Diagnosis/Clinical Criteria

1. Is this request for initial or continuing therapy?
   □ Initial therapy □ Continuing therapy, state start date: _____

2. Indicate the patient's diagnosis for the requested medication: _____

Clinical Criteria:

1. Member has a diagnosis of Attention Deficit Hyperactivity Disorder (ADHD) as confirmed by psychoeducational testing****,
   □ No □ Yes

2. **AND** indicate the member's age: _____.
   □ No □ Yes

3. **AND** member has had an adequate trial* (1 week) and/or intolerance** or allergy to the following medications:
   a. **If ordering short-acting Evekeo ODT:** dextroamphetamine-amphetamine (generic Adderall), dextroamphetamine (generic Dexedrine) and methylphenidate (generic Ritalin, Methylin)
   b. **If ordering long-acting Adzenys XR-ODT, Dyanavel XR SUER, Mydayis CP24, Vyvanse:** dextroamphetamine-amphetamine (generic Adderall XR), intermediate or long-acting methylphenidate (methylphenidate SR, methylphenidate CD, or methylphenidate ER), and dexmethylphenidate (generic Focalin XR)

   □ No □ Yes

Additional Criteria for Vyvanse:

1. Prescribed by or in consultation with a psychiatrist,
   □ No □ Yes

2. **AND** prior adequate trial* (1 week) and/or intolerance** or allergy to lisdexamfetamine (generic Vyvanse)
   □ No □ Yes

<u>If Treating Binge Eating Disorder (Vyvanse ONLY):</u>

1. Member has a diagnosis of Binge Eating Disorder (BED)***,
   □ No □ Yes

2. **AND** prescribed by or in consultation with a psychiatrist,
   □ No □ Yes

3. **AND** member has had prior adequate trial* (6 weeks) and failure of 2 formulary Selective Serotonin Reuptake Inhibitors (SSRIs) unless contraindication, intolerance, or allergy,
   □ No □ Yes

4. **AND** member has had prior adequate trial* (1 month) and failure of topiramate or atomoxetine unless contraindication, intolerance, or allergy
   □ No □ Yes

5. **AND** prior adequate trial* (1 week) and/or intolerance** or allergy to lisdexamfetamine (generic Vyvanse)
   □ No □ Yes

For continuation of therapy, please respond to <u>additional questions</u> below:

1. Member continues to meet the initial review criteria and has demonstrated positive clinical response to medication
   □ No □ Yes

NOTES:
*Adequate trial of a long-acting agent is further defined as wearing off that is not resolved by increasing the dose, AND adding a short-acting agent OR increasing frequency to twice daily OR clinically significant side effects related to the dosage form that cannot be resolved by adjusting the dose or timing
**Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment and do not require medication discontinuation
***Criteria only applies to new start patients
****Criteria only applies for 18 years of age and older

6 – Prescriber Sign-Off

Additional Information –

1. **Please submit chart notes/medical records for the patient that are applicable to this request.**
2. **If member has not tried preferred agent(s) please provide rationale/explanation and any additional supporting information that should be taken into consideration for the requested medication:**

_____
_____
_____

I certify that the information provided is accurate. Supporting documentation is available for State audits.

Prescriber Signature:	**Date:**